List view / Grid view
25 September 2012 | By Boehringer Ingelheim / Eli Lilly & Company
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will present data for three molecules, including two investigational compounds, from their Diabetes Alliance portfolio at the 48th European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin, 1–5 October 2012. Now in its second year, the Boehringer-Lilly Alliance…
24 September 2012 | By Boehringer Ingelheim / Eli Lilly and Company
Boehringer Ingelheim and Eli Lilly and Company today announced that they have received a Positive Opinion from the European Medicines Agency’s (EMA) medicinal committee recommending expanding the therapeutic indication for the DPP-4 inhibitor Trajenta® (linagliptin). If approved by the European Commission, this will expand the indicated use of Trajenta® by…
19 September 2012 | By Bristol-Myers Squibb
New non-profit organization to speed pharmaceutical R&D...
6 September 2012 | By Eli Lilly and Company
The Phase III POINTBREAK trial did not meet its primary endpoint...
4 September 2012 | By Eli Lilly and Company
Lilly Diabetes launches Lilly Glucagon Mobile App to support #diabetes caregivers...
26 August 2012 | By Eli Lilly and Company
Study did not meet primary objective of demonstrating prasugrel superiority over clopidogrel in this patient population...
17 August 2012 | By Eli Lilly and Company
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta® (linagliptin) tablets for use as add-on therapy to insulin.
7 August 2012 | By Eli Lilly and Company
Eli Lilly and Company announced data from a Phase III trial...
30 July 2012 | By Eli Lilly and Company
Data to explore future treatment possibilities for people with type 1 diabetes...
25 July 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) received Marketing Authorisation from the European Commission for Jentadueto® which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet. 1 Linagliptin/metformin hydrochloride (HCl) will provide a new, single-tablet treatment option, taken twice-daily, for adults with Type 2 Diabetes. 1
22 July 2012 | By Eli Lilly and Company
Results from a pharmacokinetic study...
11 July 2012 | By Eli Lilly and Company
Eli Lilly and Company announced negative clinical trial results...
6 July 2012 | By Abbott
Groundbreaking partnership that aims to speed the discovery of essential new treatments...
6 July 2012 | By Eli Lilly and Company
Eli Lilly and Company has met the United States FDA requirements for pediatric exclusivity for Cymbalta®...
28 June 2012 | By Boehringer Ingelheim
Results from a two-year study published in The Lancet today demonstrate that Trajenta® (linagliptin) provides similar blood glucose improvements when compared to the commonly prescribed sulphonylurea, glimepiride, in adult patients with type 2 diabetes (T2D) inadequately controlled on metformin alone. The publication also describes that linagliptin was associated with significantly…
